NEW YORK--(BUSINESS WIRE)--SolveBio, a contextual knowledge hub for genomic and phenotypic information for the life sciences industry, today announced the formation of the company’s advisory board with the appointment of four of the world’s foremost experts in genomics, biomedical data, and information technology. The SolveBio scientific and technology advisors will serve as resources and strategic partners for SolveBio and the SolveBio community in the development of new technology for better knowledge integration and usage in life sciences R&D and clinical organizations. The inaugural list of advisors can be found below.
“We are thrilled to be working with some of the top experts in genomics, data-driven medicine, and information technology,” said Mark Kaganovich, CEO of SolveBio. “The experience and knowledge of the global science and technology leaders on our advisory board will help SolveBio in our mission to work with pharma and clinicians to de-risk therapeutic development and lower R&D costs.”
Stephen Wolfram, PhD, Creator of Mathematica, Wolfram|Alpha and the Wolfram Language; author of A New Kind of Science and other books; Founder & CEO of Wolfram Research.
George Church, PhD, Professor of Genetics at Harvard Medical School and Director of the Center for Computational Genetics.
Joel Dudley, PhD, Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai (ISMMS).
Yaniv Erlich, PhD, Core Member at the New York Genome Center and Assistant Professor of Computer Science and Computational Biology at Columbia University.
SolveBio, founded in 2013, is a contextual knowledge hub focused on enabling pharma, biotech, and diagnostic organizations to effectively connect and use external and internal genomic information. SolveBio extracts, evaluates, and unifies complex, disparate biomedical data for life science enterprises. SolveBio is based in New York and is backed by Andreessen Horowitz, Max Levchin, Nat Turner, Elad Gil, SV Angel, Faridan Capital and other leading life sciences and technology investors. For more information, visit www.solvebio.com.